Keywords: telvancin, non-inferior, hap/vap, studies, california, usa-based, biopharmaceutical
Telvancin non-inferior in HAP/VAP studies
Article | 17 December 2007
California, USA-based biopharmaceutical firm Theravance says that its developmental antibiotic telavancin has met key non-inferiority endpoints in hospital-acquired pneumonia studies. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
